Key result
Editorial reviews paclitaxel-related cardiotoxicity mechanisms and clinical implications.
Answers are grounded in this paper and cite their sources.
Paclitaxel cardiotoxicity warrants ongoing clinical vigilance; Level 5 data leaves open the need for larger prospective confirmation.
Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.11.3481 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9817263 Paclitaxel and cardiotoxicity. E A PerezxE A PerezSearch for articles by this author https://doi.org/10.1200/JCO.1998.16.11.3481 PDF "Paclitaxel and cardiotoxicity.." Journal of Clinical Oncology, 16(11), pp. 3481–3482© 1998 by American Society of Clinical Oncology
No takes yet. Share an insight, caveat, or question.
Edith A. Perez (1998) conducted an editorial in Cardiotoxicity. Paclitaxel was evaluated. This editorial discusses paclitaxel and cardiotoxicity, providing no quantitative clinical trial data in the abstract.
Synapse has enriched 10 related papers. Consider them for comparative context: